Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IOP-lowering medications to prevent IOP spikes after intravitreal anti-VEGF injections
TCTR20241005001Phase 3Completed
- Sponsor
- Mettapracharak (Wat Rai Khing) Hospital
- Start
- Dec 2020
- Countries
- 1
01
Overview
Phase 3, randomised trial in retinal vascular disease, sponsored by Mettapracharak (Wat Rai Khing) Hospital. Primary endpoint: Acute intraocular pressure spike after intravitreal anti-VEGF injection. Started Dec 2020; status: completed.
02
Conditions
retinal vascular disease
Beyond the preview
Go deeper on TCTR20241005001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20241005001.